AstraZeneca doesn't plan to conduct a clinical trial to confirm that aspirin dosage caused a geographic discrepancy in the performance of its newly approved heart drug Brilinta. Some analysts had speculated such a trial might strengthen the image of the brand in the U.S., even though the company has not been asked to do so by regulators. Report